 |
|
|
| |
ViiV HEALTHCARE'S 2-DRUG REGIMEN DOVATO IS AS EFFECTIVE AS 3-DRUG REGIMEN BIKTARVY IN FIRST-OF-ITS-KIND HEAD-TO-HEAD STUDY IN TREATMENT-NAïVE ADULTS LIVING WITH HIV
|
| |
| |
Download the PDF here
full release pdf attached
Positive Week 48 data from the phase IIIb VOGUE study reinforce Dovato as an effective treatment option with fewer medicines than Biktarvy, across diverse populations
Findings build on 10 years of evidence supporting DTG/3TC as the first and only oral 2-drug regimen for treatment-naïve people living with HIV
London, 27 July 2026 - ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced data to be presented this week at the 26th International AIDS Conference (AIDS 2026) in Rio de Janeiro, Brazil, from the phase IIIb VOGUE study. Data show that Dovato (dolutegravir/lamivudine (DTG/3TC)) demonstrated non-inferior efficacy to Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF)) in treatment-naïve adults living with HIV, including people with high viral loads or a low CD4+ cell count.1 The findings also reinforced DTG/3TC's high barrier to resistance, with zero cases of treatment-emergent resistance identified across treatment arms.
Jean van Wyk, MBChB, MFPM, Chief Medical Officer at ViiV Healthcare, said: "HIV treatment is lifelong, so the number of medicines people take over decades of care can matter. As the first randomised, head-to-head study comparing DTG/3TC with BIC/FTC/TAF in treatment-naïve adults living with HIV, VOGUE adds to 10 years of real-world evidence showing that people starting treatment can successfully manage their HIV with fewer daily drugs. The data demonstrate that from day one, we can potentially reduce the number of antiretroviral drugs a person receives with DTG/3TC, without compromising on efficacy or the barrier to resistance."
The ongoing multi-country, open-label, phase IIIb VOGUE study randomised 509 treatment-naïve adults living with HIV-1 to receive either DTG/3TC (n=254) or BIC/FTC/TAF (n=255), and treatment was initiated before the availability of baseline resistance testing results. At baseline, 47% of participants had a viral load ≥100,000 copies/mL, 16% had viral load ≥500,000 copies/mL and 16% had a CD4+ cell count <200 cells/mm3.
At Week 48, virologic suppression (HIV-1 RNA <50 copies/mL) was achieved in 89% (n=226/254) of participants receiving DTG/3TC compared with 92% (n=235/255) receiving BIC/FTC/TAF (adjusted difference: -3%, 95% confidence interval [-8%, 2%]), meeting the study's non-inferiority endpoint. Median time to viral suppression was rapid and similar in both groups (4.1 weeks). No treatment-emergent resistance was identified in either arm.
The overall safety profiles for both treatment groups were comparable, with no new safety signals observed. A similar number of participants in each group (n=7 for DTG/3TC; n=7 for BIC/FTC/TAF) stopped treatment due to not achieving or maintaining viral suppression.
|
| |
|
|
|
|
|
